Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 29

  • 580 clinical trials
  • 226 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease61Bladder cancer54Transitional cell carcinoma46Renal cell carcinoma42Bladder transitional cell carcinoma33IgA nephropathy23Acute kidney injury21Non-small cell lung cancer19Lupus nephritis18Clear cell renal cell carcinoma17Urinary tract infection17Paroxysmal nocturnal haemoglobinuria16Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

580 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

580 clinical trials

Chronic kidney disease

Not recruiting

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Congenital cystic kidney disease

Not recruiting

Study of ABBV-CLS-628 to evaluate safety and effectiveness in adults with Autosomal Dominant Polycystic Kidney Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:ABBV-CLS-628
  • Sponsor:Calico Life Sciences LLC

Kidney transplant rejection

Not recruiting

Study of Felzartamab for Patients with Late Antibody-Mediated Rejection After Kidney Transplant

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Felzartamab
  • Sponsor:Biogen Idec Research Limited

Renal impairment

Not recruiting

Study on How Kidney Function Affects the Drug GS-5245 in Patients With Normal and Impaired Kidney Function

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Gs-5245
  • Sponsor:Gilead Sciences Inc.

Bladder transitional cell carcinoma

Not recruiting

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Diabetic nephropathy

Not recruiting

Study on Hyperpolarized [1-13C]Pyruvate and Meglumine Gadoterate for Patients with Diabetic Kidney Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Meglumine Gadoterate
  • Sponsor:Aarhus University

Chronic kidney disease+1

Not recruiting

Study on the Effects of Camostat Mesilate for Kidney Protection in Patients with Chronic Kidney Disease and Proteinuria

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:CAMOSTAT MESILATE
  • Sponsor:Odense University Hospital

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Safety and Effectiveness of Crovalimab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Crovalimab
  • Sponsor:F. Hoffmann-La Roche AG

Type 1 diabetes mellitus+1

Not recruiting

Study on the Effectiveness and Safety of Finerenone for Patients with Chronic Kidney Disease and Type 1 Diabetes

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Endometrial cancer+4

Not recruiting

Study on Raludotatug Deruxtecan for Patients with Advanced or Metastatic Solid Tumors, Including Gynecological and Genitourinary Cancers

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Raludotatug Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Acute kidney injury

Not recruiting

Study of GDC-8264 compared to placebo for preventing kidney injury in patients at risk of acute kidney injury after heart surgery

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7288817
  • Sponsor:Genentech Inc.

Renal failure+1

Not recruiting

Study on Reducing Tacrolimus Dose in Kidney Transplant Patients Using LCPT Compared to Tacrolimus-ER

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Amsterdam UMC Stichting

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trialsNivolumab36 clinical trialsMycophenolate Mofetil24 clinical trialsDapagliflozin23 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.